The Fly

iVexSol closes $23.8M Series A-3 financing

iVexSol announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (BMY), Charles River Laboratories (CRL) and Asahi Kasei Medical, a division of Asahi Kasei (AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (BLFS) to close Series A financing at a total of more than $39 million. The new funding will be used to invest in iVexSol’s Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory and cGMP operations, and augmenting existing infrastructure to support the production of stable LVV producer cell lines.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More